Upadacitinib (ABT-494)

Catalog No. A18316

Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM. IC50 & Target: IC50: 43 nM (JAK1), 200 nM (JAK2)
Catalog Num A18316
M. Wt 380.37
Formula C17H19F3N6O
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1310726-60-3
Synonyms ABT 494, ABT494
SMILES CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM. IC50 & Target: IC50: 43 nM (JAK1), 200 nM (JAK2)
In vitro DMSO 66 mg/mL (173.51 mM)
Water Insoluble
Ethanol 66 mg/mL (173.51 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 26.29 mL 131.45 mL 262.9 mL
0.5 mM 5.26 mL 26.29 mL 52.58 mL
1 mM 2.63 mL 13.15 mL 26.29 mL
5 mM 0.53 mL 2.63 mL 5.26 mL

*The above data is based on the productmolecular weight 380.37. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.